Loading company…
PROMEDIGEN develops protein-based treatments for cancer and neurodegenerative disorders.
PROMEDIGEN develops treatments for cancer and neurodegenerative disorders using protein engineering technology for post-translational modifications. Its work includes proteins targeting cancer-specific targets and drug resistance. Founded in 2019, it is based in Daejeon, South Korea. In June 2020, it secured KRW 2 billion in funding from Company K Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in